
Proposed Amendment


We claim:

~~1. A method for minimizing the bone loss~~ effect of a compound of formula I



I

wherein R is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$ or $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, and wherein said formula I compound is administered to a mammal in need of treatment, comprising concurrently or sequentially administering to said mammal an effective amount of a compound of formula II



II

wherein

each R^1 is independently -H, -OH, $-O(C_1-C_4$ alkyl), $-OCOC_6H_5$, $-OCO(C_1-C_6$ alkyl), or $-OSO_2(C_4-C_6$ alkyl); ~~and~~

~~R^2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-~~ pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof.

2. A method according to Claim 1 wherein R of said formula I compound is $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutical acceptable salt thereof, each R^1 of said formula II compound is -OH, and R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof.

3. A method according to Claim 2 wherein said mammal in need of treatment of a compound of formula I is a human female.

4. A method according to Claim 3 wherein said female is suffering from breast cancer.

5. A method according to Claim 3 wherein said female is suffering from endometriosis or uterine fibroid disease.

6. A method according to Claim 1 wherein R of said formula I compound is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$, or a pharmaceutically acceptable salt thereof, each R^1 of a formula II compound is -OH, and R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof.

7. A method according to Claim 6 wherein said mammal in need of treatment of a compound of formula I is a human female.

8. A method according to Claim 7 wherein said ~~female is suffering from breast cancer.~~

~~9. A method according to Claim 7 wherein said~~ female is suffering from endometriosis or uterine fibroid disease.

10. A method for minimizing bone loss comprising the method of Claim 1 and further comprising administering to said mammal an effective amount of a bone anabolic agent.


11. A method according to Claim 10 wherein R of said formula I compound is $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, each R^1 of said formula II compound is -OH, R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

12. A method according to Claim 11 wherein said mammal in need of treatment of a compound of formula I is a human female.

13. A method according to Claim 12 wherein said female is suffering from breast cancer, endometriosis, or uterine fibroid disease.

14. A method according to Claim 10 wherein R of said formula I compound is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$, or a pharmaceutically acceptable salt thereof, each R^1 of said formula II compound is -OH, R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

15. A method for minimizing the bone loss ~~effect of a compound of formula I~~



I

wherein R is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$ or $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, and wherein said formula I compound is administered to a mammal in need of treatment, comprising concurrently or sequentially administering to said mammal an effective amount of a bone anabolic agent.

16. A method according to Claim 15 wherein R of said formula I compound is $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

17. A method according to Claim 16 wherein said mammal in need of treatment of a compound of formula I is a human female.


18. A method according to Claim 17 wherein said female is suffering from breast cancer, endometriosis, or uterine fibroid disease.

19. A method according to Claim 15 wherein R of said formula I compound is $-CH_2CON(CH_2)_3$-n-$CH_2CH_2CH_2CH_3$, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

~~20. A method according to Claim 19 wherein said~~ mammal in need of treatment of a compound of formula I is a human female.


21. A method according to Claim 20 wherein said female is suffering from breast cancer, endometriosis, or ~~uterine fibroid disease.~~

22. A pharmaceutical composition comprising a compound of formula I



I

wherein R is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$ or $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, a compound of formula II



II

wherein

each R^1 is independently -H, -OH, -O(C_1-C_4 alkyl), -OCOC$_6$H$_5$, -OCO(C_1-C_6 alkyl), or -OSO$_2$(C_4-C_6 alkyl); and

R^2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof; and

optionally, a bone anabolic agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

2 ~~23~~. A pharmaceutical composition according to Claim 1 ~~22~~ wherein R of said formula I compound is -SO$(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, each R^1 of said formula II compound is -OH, and R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof.

3 ~~24~~. A pharmaceutical composition according to Claim 2 ~~23~~ wherein said optional bone anabolic agent is parathyroid hormone (1-84) or (1-34).

4 ~~25~~. A pharmaceutical composition according to Claim 2 ~~23~~ wherein said composition is used for minimizing bone loss from administration of said formula I compound.

5 ~~26~~. A pharmaceutical composition according to Claim 3 ~~24~~ wherein said composition is used for minimizing bone loss from administration of said formula I compound.


6 ~~27~~. A pharmaceutical composition according to Claim 1 ~~22~~ wherein R of said formula I compound is -$CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$, or a pharmaceutically acceptable salt thereof, each R^1 of said formula II compound is -OH, and R^2 of said formula II compound is 1-piperidinyl, or a pharmaceutically acceptable salt thereof.

7
28. A pharmaceutical composition according to Claim 6 27 wherein said optional bone anabolic agent is parathyroid hormone (1-84) or (1-34).

8
29. A pharmaceutical composition according to Claim 6 27 wherein said composition is used for minimizing bone loss from administration of said formula I compound.

9
30. A pharmaceutical composition according to Claim 7 28 wherein said composition is used for minimizing bone loss from administration of said formula I compound.

10
31. A pharmaceutical composition comprising a compound of formula I



I

wherein R is $-CH_2CON(CH_3)$-n-$CH_2CH_2CH_2CH_3$ or $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, and a bone anabolic agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

11
32. A pharmaceutical composition according to Claim 10 31 wherein R of said formula I compound is $-SO(CH_2)_3CF_2CF_3$, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

12
~~33~~. A pharmaceutical composition according to Claim 11 ~~32~~ wherein said composition is used for minimizing bone loss from administration of said formula I compound.

13
~~34~~. A pharmaceutical composition according to Claim 10 ~~31~~ wherein R of said formula I compound is $-CH_2CON(CH_3)-n-CH_2CH_2CH_2CH_3$, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

14
~~35~~. A pharmaceutical composition according to Claim 13 ~~34~~ wherein said composition is used for minimizing bone loss from administration of said formula I compound.

Add new claims 15 to 35. →